Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: Quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist

European Journal of Cancer

Volumn 36, Issue 12, 2000, Pages 1488-1497

  Kramer, J A ^a   Curran, D ^a   Piccart, M ^b   De Haes, J C J M ^c   Bruning, P F ^d   Klijn, J G M ^e   Bontenbal, M ^e   Van Pottelsberghe, C ^a   Groenvold, M ^f   Paridaens, R ^g  

^a EORTC DATA CENTER   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f BISPEBJERG HOSPITAL   (Denmark)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; EORTC QLQ C30; Quality of life; Rotterdam Symptom Checklist

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ADVANCED CANCER; ANOREXIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; PACLITAXEL; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0033860004     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00134-9     Document Type: Article

References (17)

1. Harris J.R., Morrow M., Norton L. Malignant tumors of the breast. Chapter 36.2. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: Principles & Practice of Oncology, 5th edn. 1997;1602 Philadelphia, Lippincott-Raven.
2. Coates A, Gebski V, Bishop JF, et al. for the Australian-New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987, 317, 1490-1495.
3. Richards M.A., Hopwood P., Ramirez A.J.et al. Doxorubicin in advanced breast cancer. influence of schedule on response, survival and quality of life Eur J Cancer. 28A:1992;1023-1028.
4. Ramirez A.J., Towlson K.E., Leaning M.S., Richards M.A., Rubens R.D. Do patients with advanced breast cancer benefit from chemotherapy? Br. J. Cancer. 78:1998;1488-1494.
5. de Haes J.C.J.M., van Knippenberg F.C.E., Neijt J.P. Measuring psychological and physical distress in cancer patients. structure and application of the Rotterdam Symptom Checklist Br. J. Cancer. 62:1990;1034-1038.
6. Aaronson N.K., Ahmedzai S., Bergman B.et al. The European Organization for Research and Treatment of Cancer QLQ-C30. a quality of life instrument for use in international clinical trials in oncology J. Natl. Cancer Inst. 85:1993;365-376.
7. Paridaens R., Biganzoli L., Bruning P.et al. Taxol® versus doxorubicin as first-line single agent chemotherapy for metastatic breast cancer - an EORTC randomized study with crossover. J. Clin. Oncol. 18:2000;724-733.
8. Fayers P., Aaronson N., Bjordal K., Curran D., Groenvold M. EORTC QLQ-C30 Scoring Manual. 2nd edn. 1999;EORTC Quality of Life Study Group, Brussels.
9. de Haes J.C.M., Olschewski M., Fayers P.et al. Measuring the quality of life of cancer patients with The Rotterdam Symptom Checklist (RSCL). A Manual. 1996;Northern Centre for Healthcare Research, University of Groningen, The Netherlands.
10. Fayers P., Weeden S., Curran D., on behalf of the E.O.R.T.C. Quality of Life Study Group. EORTC QLQ-C30 Reference Values. 1998;EORTC Quality of Life Study Group, Brussels.
11. Pocock S.J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 31:1975;103-115.
12. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
13. Hollander M., Wolfe D.A. Nonparametrics Statistical Methods. 1973;John Wiley & Sons, New York.
14. SAS/STAT Software. Changes and Enhancements 6.11. Cary NC, USA, SAS Institute Inc., 1996.
15. Hurny C., Bernhard J., Joss R.et al. for the Swiss Group for Clinical Cancer Research SAKK. Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer - a lesson from the real world. Ann. Oncol. 3:1992;825-831.
16. Hopwood P., Stephens R.J., Machin D., for the M.R.C. Lung Cancer Working Party. Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual. Life Res. 3:1994;339-352.
17. Hopwood P., Harvey A., Davies J.et al. Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. Eur. J. Cancer. 34:1998;49-57.